Piper Sandler Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price

Amneal Pharmaceuticals (NASDAQ:AMRX) had its price target boosted by Piper Sandler from $9.00 to $11.00 in a research note released on Monday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Other equities research analysts have also issued research reports about the company. Barclays raised their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a report on Friday, September 6th. Finally, Truist Financial increased their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $10.00.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX opened at $9.00 on Monday. The firm has a market cap of $2.79 billion, a P/E ratio of -13.28 and a beta of 1.17. The stock’s 50-day moving average is $8.56 and its 200-day moving average is $7.62. Amneal Pharmaceuticals has a one year low of $4.16 and a one year high of $9.48.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Profund Advisors LLC grew its stake in Amneal Pharmaceuticals by 8.1% in the second quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock valued at $143,000 after purchasing an additional 1,680 shares in the last quarter. ProShare Advisors LLC grew its stake in Amneal Pharmaceuticals by 8.6% in the first quarter. ProShare Advisors LLC now owns 21,902 shares of the company’s stock valued at $133,000 after purchasing an additional 1,726 shares in the last quarter. SG Americas Securities LLC grew its stake in Amneal Pharmaceuticals by 18.8% in the first quarter. SG Americas Securities LLC now owns 20,112 shares of the company’s stock valued at $122,000 after purchasing an additional 3,177 shares in the last quarter. Rothschild Investment LLC bought a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $26,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Amneal Pharmaceuticals by 13.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after acquiring an additional 4,115 shares during the period. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.